Optimizing expedited regulatory pathways to speed time to market

Regulatory strategies to deliver innovative therapies to patients faster

Speeding therapies to market is no longer just about faster development—it requires a smarter regulatory strategy across regions, pathways and approval models.

This eBook explores how life sciences organizations are using expedited regulatory pathways, reliance procedures and global regulatory collaboration to accelerate approvals while maintaining regulatory rigor.

Inside, we examine how facilitated regulatory pathways are being applied across the U.S., E.U. and Japan, where they deliver the greatest impact, and how companies are sequencing approvals globally to reduce duplication, uncertainty and time to market. You’ll also discover how regulatory intelligence can support better decision-making earlier in development—helping teams navigate evolving requirements and identify opportunities to accelerate market access.

By downloading this eBook, you’ll learn:

• How expedited regulatory pathways are shaping modern drug approvals across major global markets
• Where pathways such as Accelerated Approval, Priority Review, PRIME, Conditional Marketing Authorisation and Sakigake deliver the greatest value—and the considerations associated with each
• How reliance procedures can be used to extend an initial approval into additional markets more efficiently
• How global consortia and parallel review initiatives, including Project Orbis, the Access Consortium and EMA OPEN, can help reduce approval timelines
• Why submission sequencing and coordinated regulatory planning are critical to successful global market access strategies
• How regulatory intelligence enables teams to compare requirements, anticipate regulatory change and plan submissions with greater confidence